8th DIA Cardiac Safety Workshop in Japan

Atsushi Sugiyama, MD, PhD

Professor and Chairman, Department of Pharmacology

Kyosuke Takeshita, MD, PhD

Department of Clinical Laboratory Medicine

Replacing the Thorough QT study with Concentration-QTc analysis applied to First-in-Human studies – recent trends and experience from interactions with regulators

Börje C. Darpö, MD, PhD

Clario, Sweden

Chief Scientific Officer, Cardiac Safety

Current status and future perspective of clinical proarrhythmic risk assessment from a regulatory point of view

Kaori Shinagawa, MD, PhD

Pharmaceuticals and Medical Devices Agency (PMDA), Japan

Senior Scientist for Clinical Medicine, Office of New Drug II

Reasons why it is difficult to evaluate cardiac safety for antidiabetic drugs - Findings obtained in a type 1 diabetes study examining the effects of diet on normal and insulin-deficient subjects

Jorg Taubel, MD, FFPM

Richmond Pharmacology, United Kingdom

Chief Executive Officer

Boaz Mendzelevski, MD

Boaz Mendzelevski, MD

Cardiac Safety Consultants Ltd., United Kingdom

Consultant Cardiologist